ArticlePharmacoEconomics - open2018
Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis.
Article in PharmacoEconomics - open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies.BMC health services research · 2020Pooled it
- Economic burden of type 2 diabetes management in France according to clinical characteristics.Diabetes, obesity & metabolism · 2026Article
- Ten-Year Trends in Healthcare Use and Costs for People Living with Diabetes in France: Results from the Epicodiab Study Based on National Claims Data.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Review
- Article
- Nationwide Trends in Type 1 and Type 2 Diabetes in France (2010-2019): A Population-Based Study Using a Machine Learning Classification Algorithm.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Lights and Shadows of Bariatric Surgery: Insights from a Nationwide Administrative Database of People Living with Type 1 Diabetes and Obesity.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Article
- Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.Journal of comparative effectiveness research · 2024Article
- The Socio-Economic Cost of Diabetes Mellitus in Korea Using National Health Insurance Claim Data, 2017.Healthcare (Basel, Switzerland) · 2022Article
- Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016-2018.PharmacoEconomics - open · 2022Article
- Observational
- Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study.Diabetes care · 2021Article
- Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France.PharmacoEconomics - open · 2021Article
- Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data.BMC public health · 2021Article
- Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Review
- Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System.International journal of environmental research and public health · 2020Article
- Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Type 2 diabetes and healthcare resource utilisation in the Kingdom of Bahrain.BMC health services research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOur objects was to estimate the direct healthcare costs of type 2 diabetes mellitus (T2DM) in France in 2013.
methodsData were drawn from a random sample of ≈600,000 patients registered in the French national health insurances database, which covers 90% of the French population. An algorithm was used to select patients with T2DM. Direct healthcare costs from a collective perspective were derived from the database and compared with those from a control group to estimate the cost of diabetes and related comorbidities. Overall direct costs were also compared according to the diabetes therapies used throughout the year 2013.
resultsCost analysis was available for a sample of 25,987 patients with T2DM (mean age 67.5 ± standard deviation 12.5; 53.9% male) matched with a control group of 76,406 individuals without diabetes. Overall per patient per year medical expenditures were €6506 ± 10,106 in the T2DM group as compared with €3668 ± 6954 in the control group. The cost difference between the two groups was €2838 per patient per year, mainly due to hospitalizations, medication and nursing care costs. Total per capita annual costs were lowest for patients receiving metformin monotherapy (€4153 ± 6170) and highest for those receiving insulin (€12,890). However, apart from patients receiving insulin, costs did not differ markedly across the different oral treatment patterns.
conclusionExtrapolating these results to the whole T2DM population in France, total direct costs of diagnosed T2DM in 2013 was estimated at over €8.5 billion. This estimate highlights the substantial economic burden of this condition on society.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.